Protection against malaria by immunization with non-attenuated sporozoites under single-dose piperaquine-tetraphosphate chemoprophylaxis

Vaccine

Volumn 32, Issue 45, 2014, Pages 6005-6011

  Pfeil, Johannes ^a,b   Sepp, Katharina Jutta ^a,b   Heiss, Kirsten ^a,f   Meister, Michael ^e   Mueller, Ann Kristin ^a,b   Borrmann, Steffen ^c,d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b German Centre for Infection Research (DZIF)   (Germany)

^c German Center for Research in Infectious Disease (DZIF)   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f MalVa GmbH   (Germany)

Author keywords

Malaria; Malaria vaccination; Piperaquine; Piperaquine tetraphosphate; Plasmodium; Whole sporozoite immunization

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; HERMES ANTIGEN; L SELECTIN; MALARIA VACCINE; PIPERAQUINE; SPOROZOITE VACCINE; CHLOROQUINE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNIZATION; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PLASMODIUM BERGHEI INFECTION; RODENT MALARIA; SINGLE DRUG DOSE; SPOROZOITE; WHOLE BODY IMAGING; ANIMAL; C57BL MOUSE; CHEMOPROPHYLAXIS; DISEASE MODEL; FEMALE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LIVER; MALARIA; PLASMODIUM BERGHEI; SPLEEN;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOPREVENTION; CHLOROQUINE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOLOGIC MEMORY; LIVER; MALARIA; MALARIA VACCINES; MICE, INBRED C57BL; PLASMODIUM BERGHEI; QUINOLINES; SPLEEN; SPOROZOITES;

EID: 84908005772     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.112     Document Type: Article

References (27)

1. Murray C.J., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379(Feburary (9814)):413-431.
2. Heppner D.G. The malaria vaccine - status quo 2013. Travel Med Infect Dis 2013, 11(January-Feburary (1)):2-7.
3. Epstein J.E., Richie T.L. The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review. Curr Opin Infect Dis 2013, (October (5)):420-428.
4. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216(5111):160-162.
5. Mueller A.K., Labaied M., Kappe S.H., Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005, 433(January (7022)):164-167.
6. Beaudoin R.L., Strome C.P., Mitchell F., Tubergen T.A. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 1977, 42(June (1)):1-5.
7. Belnoue E., Costa F.T., Frankenberg T., Vigario A.M., Voza T., Leroy N., et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004, 172(Febuary (4)):2487-2495.
8. Belnoue E., Voza T., Costa F.T., Gruner A.C., Mauduit M., Rosa D.S., et al. Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. J Immunol 2008, 181(December (12)):8552-8558.
9. Friesen J., Matuschewski K. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 2011, 29(September (40)):7002-7008.
10. Renia L., Gruner A.C., Mauduit M., Snounou G. Vaccination using normal live sporozoites under drug treatment. Methods Mol Biol 2013, 923:567-576.
11. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361(July (5)):468-477.
12. Friesen J., Borrmann S., Matuschewski K. Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance. Antimicrob Agents Chemother 2011, 55(June (6)):2760-2767.
13. Friesen J., Silvie O., Putrianti E.D., Hafalla J.C., Matuschewski K., Borrmann S. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med 2010, 2(July (40)):40ra9.
14. Davis T.M., Hung T.Y., Sim I.K., Karunajeewa H.A., Ilett K.F. Piperaquine: a resurgent antimalarial drug. Drugs 2005, 65(1):75-87.
15. Batty K.T., Moore B.R., Stirling V., Ilett K.F., Page-Sharp M., Shilkin K.B., et al. Toxicology and pharmacokinetics of piperaquine in mice. Toxicology 2008, 249(July (1)):55-61.
16. Hung T.Y., Davis T.M., Ilett K.F., Karunajeewa H., Hewitt S., Denis M.B., et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004, 57(March (3)):253-262.
17. Lewis M.D., Pfeil J., Mueller A.K. Continuous oral chloroquine as a novel route for Plasmodium prophylaxis and cure in experimental murine models. BMC Res Notes 2011, 4:262.
18. Janse C.J., Franke-Fayard B., Mair G.R., Ramesar J., Thiel C., Engelmann S., et al. High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol Biochem Parasitol 2006, 145(January (1)):60-70.
19. Ploemen I.H., Prudencio M., Douradinha B.G., Ramesar J., Fonager J., van Gemert G.J., et al. Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS ONE 2009, 4(11):e7881.
20. Schmidt N.W., Butler N.S., Badovinac V.P., Harty J.T. Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathogens 2010, 6(7):e1000998.
21. Nganou-Makamdop K., van Gemert G.J., Arens T., Hermsen C.C., Sauerwein R.W. Long term protection after immunization with P. berghei sporozoites correlates with sustained IFNgamma responses of hepatic CD8+ memory T cells. PLoS ONE 2012, 7(5):e36508.
22. Guebre-Xabier M., Schwenk R., Krzych U. Memory phenotype CD8(+) T cells persist in livers of mice protected against malaria by immunization with attenuated Plasmodium berghei sporozoites. Eur J Immunol 1999, December (12):3978-3986.
23. Bassat Q., Mulenga M., Tinto H., Piola P., Borrmann S., Menendez C., et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS ONE 2009, 4(11):e7871.
24. Naing C., Mak J.W., Aung K., Wong J.Y. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies. Trans R Soc Trop Med Hyg 2013, 107(Feburary (2)):65-73.
25. Karunajeewa H.A., Ilett K.F., Mueller I., Siba P., Law I., Page-Sharp M., et al. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother 2008, 52(January (1)):237-243.
26. Aponte J.J., Schellenberg D., Egan A., Breckenridge A., Carneiro I., Critchley J., et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009, 374(October (9700)):1533-1542.
27. Doua J.Y., Matangila J., Lutumba P., Van Geertruyden J.P. Intermittent preventive treatment: efficacy and safety of sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine plus piperaquine regimens in schoolchildren of the Democratic Republic of Congo: a study protocol for a randomized controlled trial. Trials 2013, 14(September (1)):311.